Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.

Hong-Ki MinHae-Rim KimSang-Heon LeeYeon Sik HongMoon-Young KimSung-Hwan ParkKwi Young Kang

Published in: Rheumatology (Oxford, England) (2021)

In AS patients with previous exposure to a TNFi, switching biologics to secukinumab and switching to an alternative TNFi resulted in comparable drug retention and clinical efficacy.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
disease activity
randomized controlled trial
systemic lupus erythematosus
emergency department
adverse drug
drug induced